You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs in Registration / Phase 3

Key Biosimilars Programs in Registration / Phase 3

Key Programs in Phase 2

Pipeline date and pdf

Pipeline Snapshot as of April 30, 2019

  • Discovery Projects
  • Phase 1
    34
  • Phase 2
    30
  • Phase 3
    23
  • Registration
    10
  • Total97
 
Compound Name
Indicationsort descending
Phase
Submission Type
Compound Type
Lorbrena (lorlatinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
1st Line ALK Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Gastric Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Merkel Cell Carcinoma (MCC) (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (U.S.) / (E.U.) (BREAKTHROUGH - U.S.)
Project advanced
Registration Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Anti PD-L1
Go to clinical trial
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
lorlatinib (PF-06463922)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
ALK Inhibitor
Go to clinical trial
2nd Line ALK Non-Small Cell Lung Cancer (E.U.) Registration New Molecular Entity Small Molecule
Talzenna (talazoparib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PARP inhibitor
Go to clinical trial
2nd Line Metastatic Castration-Resistant Prostate Cancer Phase 2 Product Enhancement Small Molecule
rivipansel (GMI-1070)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Pan-Selectin Antagonist
Go to clinical trial
Acute vaso-occlusive crises associated with sickle cell disease in patients aged 6 years and above (FAST TRACK, ORPHAN - U.S., E.U.) Phase 3 New Molecular Entity Small Molecule
somatrogon (PF-06836922)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Human Growth Hormone Agonist
Go to clinical trial
Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) Phase 3 New Molecular Entity Biologic
PF-06700841
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
TYK2/JAK1
Go to clinical trial
Alopecia Areata Phase 2 New Molecular Entity Small Molecule
PF-06651600
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
JAK3
Go to clinical trial
Alopecia Areata (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
Xeljanz (tofacitinib)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Ankylosing Spondylitis Phase 3 Product Enhancement Small Molecule
PF-04965842
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Atopic Dermatitis (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
PF-06817024
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Cytokine Modulator
Go to clinical trial
Atopic Dermatitis (Biologic) Phase 1 New Molecular Entity Biologic
crisaborole (PF-06940799)
Therapeutic Area:
Inflammation & Immunology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
PDE4 Inhibitor
Go to clinical trial
Atopic Dermatitis (E.U.) Registration New Molecular Entity Small Molecule
PF-06873600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
CDK 2,4,6 inhibitor
Go to clinical trial
Breast Cancer Metastatic Phase 1 New Molecular Entity Small Molecule
PF-06946860
Therapeutic Area:
Internal Medicine
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Growth Factor Blocker
Go to clinical trial
Cachexia (Biologic) Phase 1 New Molecular Entity Biologic